Description: CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Home Page: www.csl.com.au
45 Poplar Road
Parkville,
VIC
3052
Australia
Phone:
61 3 9389 1911
Officers
| Name | Title |
|---|---|
| Mr. Paul R. Perreault B.A. | MD, CEO & Exec. Director |
| Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer |
| Dr. Paul F. McKenzie Ph.D. | COO & Exec. Director |
| Mr. Mark Dehring | Head of Investor Relations |
| Mr. Gregory Boss B.S., BS(Hons), J.D. | Exec. VP of Legal & Group Gen. Counsel |
| Christina Hickie | Sr. Mang. of Communications |
| Ms. Elizabeth Walker B.A., M.S. | Exec. VP & Chief HR Officer |
| Dr. Karen Etchberger | Exec. VP of Quality & Bus. Services |
| Dr. Wilfried Freudenberg | Department Head of Albumin & Immunoglobulins Production |
| Ms. Jemimah Brennan | Head of Communications - Asia Pacific |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 43.1034 |
|---|---|
| Trailing PE: | 41.2009 |
| Price-to-Book MRQ: | 6.6463 |
| Price-to-Sales TTM: | 9.304 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 30000 |